Award
NIH Reporter #5R44CA310518-02
CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
Recipient
EMBIOSYS INC.
Award Amount
$870,482.00
Ceiling
$870,482.00
Awarded
September 11, 2026
Identifier
5R44CA310518-02
The National Cancer Institute awarded EMBIOSYS INC. $870,482 for a project developing a wearable, non-invasive device to deliver induced electric field therapy and assess its safety and efficacy in combination with standard treatment for triple-negative breast cancer.
Description
Funding for research developing and evaluating a wearable device that delivers induced electric field therapy alongside standard chemotherapy for high-risk triple-negative breast cancer.